Brief: Cytek Biosciences Q2 Revenue USD 45.602 Million Vs. IBES Estimate USD 46.3 Million

Cytek Biosciences

06/08/2025 21:05

Overview

Cytek Q2 2025 revenue falls 2%, missing analyst expectations, per LSEG data

Net loss narrows to $5.6 mln from $10.4 mln in Q2 2024

Co launches Cytek Aurora Evo system and repurchases $4.5 mln stock in the qtr

Outlook

Cytek narrows 2025 revenue guidance to $196 mln-$205 mln

Company expects full-year revenue growth of -2% to +2%

Result Drivers

REVENUE DECLINE - Lower product revenue in EMEA and APAC contributed to a 2% decline in total revenue

RECURRING REVENUE GROWTH - Service and reagent revenues grew 16%, accounting for 32% of last 12 months' total revenue

INSTRUMENT EXPANSION - Installed base grew by 146 units, representing 3% unit growth, despite challenging macro environment

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$45.60 mln
$46.30 mln (4 Analysts)
Q2 Net Income
-$5.58 mln
Q2 Adjusted EBITDA
$1.27 mln
Q2 Adjusted Gross Margin
52.0%
Q2 Pretax Profit
-$6.78 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Cytek Biosciences Inc is $5.50, about 29.5% above its August 5 closing price of $3.88

Press Release: ID:nGNXbVtGtv

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)